See the DrugPatentWatch profile for azilect
What does “patentudlob azilect” mean in Denmark?
“Patentudløb” means “patent expiry.” So “patentudløb Azilect Denmark” refers to when the Azilect (rasagiline) patent protection ends in Denmark, allowing lower-cost competition later.
When does Azilect’s patent expire in Denmark?
I don’t have any provided patent-life or Denmark-specific expiry dates for Azilect in the information available here, so I can’t state an exact expiry date for Denmark without the underlying patent/market-exclusivity documents.
If you share either:
- the Danish patent number(s) (or a link), or
- the specific country/region of the patent record you’re looking at (EP vs DK national patent), or
- the marketing authorization details (product name and MA holder),
…I can help interpret the filing/priority dates and how they translate into an expiry window.
Why the expiry date can differ (patents vs “SPC” vs other exclusivity)
Even when a “main patent” ends, companies may still block generic or biosimilar entry in Europe through:
- supplementary protection certificates (SPC) linked to the drug’s marketing authorization, and/or
- additional patent families (formulations, dosing, new salts/processes),
- regulatory exclusivity terms that aren’t the same as patent expiry.
So a Denmark “patent expiry” search often ends up mixing multiple legal instruments, which is why the exact date depends on which right you mean.
How to find the exact Denmark date quickly
To get the correct “Azilect patent expiry” date for Denmark, look up the following for the relevant product:
- The Danish national patent status (or corresponding EP validation in Denmark).
- Whether an SPC exists for Azilect in Denmark.
- Any listed patent events around “expiration,” “lapse,” or “in force/expired.”
If you tell me what source you’re using (e.g., a specific register site or document), I can help you read it and extract the correct date.
What happens after expiry in Denmark?
After the relevant exclusivity/patent protection ends, generic competitors can often launch if:
- they meet regulatory requirements (quality, bioequivalence, etc.),
- they don’t face other still-active patents covering the product.
If multiple patents exist, entry timing can be staggered.
---
Sources: None provided in the prompt.